Neutre
Eli Lilly's stock slips 0.8% to $1,245.68 amid mixed news.
Ce briefing n’est pas encore disponible dans cette langue — version anglaise affichée.
Eli Lilly's stock experienced a slight decline of 0.8%, closing at $1,245.68. This movement occurred despite the FDA's clearance of the Elecsys pTau217 Alzheimer's biomarker blood test and the launch of its oral GLP-1 pill, Foundayo, in UK pharmacies. Both developments were largely anticipated by the market, leading to a muted stock response.
Points clés
- FDA clears Elecsys pTau217 Alzheimer's test.
- Foundayo oral GLP-1 pill launched in UK.
- Germany warns of €45 billion annual cost for weight-loss injections.
- ATAI Beckley reports Q2 earnings ahead of Lilly's $2.8 billion acquisition.
Sources
Généré par IA à partir de sources d'actualités publiques. Ceci n'est pas un conseil financier.
